What is the share price of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) today?
The share price of OXYGENTAPH as on 20th May 2025 is ₹90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Oxygenta Pharmaceutical Ltd (OXYGENTAPH) share?
The past returns of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) share are- Past 1 week: 9.71%
- Past 1 month: 12.66%
- Past 3 months: 10.59%
- Past 6 months: 20.56%
- Past 1 year: 143.84%
- Past 3 years: 263.00%
- Past 5 years: 829.99%
What are the peers or stocks similar to Oxygenta Pharmaceutical Ltd (OXYGENTAPH)?
The peers or stocks similar to Oxygenta Pharmaceutical Ltd (OXYGENTAPH) include:What is the market cap of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) is ₹330.93 Cr as of 20th May 2025.What is the 52 week high and low of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) share?
The 52-week high of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) is ₹108.64 and the 52-week low is ₹30.What is the PE and PB ratio of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) stock?
The P/E (price-to-earnings) ratio of Oxygenta Pharmaceutical Ltd (OXYGENTAPH) is -95.09. The P/B (price-to-book) ratio is -16.44.Which sector does Oxygenta Pharmaceutical Ltd (OXYGENTAPH) belong to?
Oxygenta Pharmaceutical Ltd (OXYGENTAPH) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Oxygenta Pharmaceutical Ltd (OXYGENTAPH) shares?
You can directly buy Oxygenta Pharmaceutical Ltd (OXYGENTAPH) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Oxygenta Pharmaceutical Ltd
OXYGENTAPH Share Price
90.000.58% (+0.52)
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
How to use scorecard? Learn more
OXYGENTAPH Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -2,068.30 | -16.44 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 44.82 | 6.38 | 0.56% |
OXYGENTAPH Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
OXYGENTAPH Company Profile
Oxygenta Pharmaceutical Limited manufactures bulk drugs and active pharmaceutical ingredients (API), including a range of pharmaceutical preparations and organic fine chemicals.
OXYGENTAPH Similar Stocks (Peers)
Compare with peersSUNPHARMA
PE Ratio
43.35
1Y Return
12.28%
Buy Reco %
88.24
CIPLA
PE Ratio
22.85
1Y Return
3.42%
Buy Reco %
75.00
TORNTPHARM
PE Ratio
67.49
1Y Return
23.16%
Buy Reco %
68.00
MANKIND
PE Ratio
55.31
1Y Return
22.99%
Buy Reco %
81.25
DRREDDY
PE Ratio
17.93
1Y Return
5.45%
Buy Reco %
53.33
OXYGENTAPH Forecasts
OXYGENTAPH Forecast
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
OXYGENTAPH
Income
Balance Sheet
Cash Flow
Annual Normal View
OXYGENTAPH Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 12.43 | 8.77 | 14.23 | 20.82 | 17.74 | 54.31 | 61.88 | 31.13 | 39.74 | 71.89 | ||||||||||
Raw Materials | 8.31 | 5.96 | 9.51 | 17.75 | 14.99 | 43.02 | 42.67 | 28.64 | 35.06 | 80.31 | ||||||||||
| Power & Fuel Cost | 1.21 | 1.08 | 1.12 | 0.89 | 1.00 | 2.79 | 3.04 | 4.16 | 4.15 | |||||||||||
| Employee Cost | 3.07 | 2.86 | 2.90 | 2.71 | 2.50 | 4.08 | 0.58 | 5.74 | 5.87 | |||||||||||
| Selling & Administrative Expenses | 1.37 | 1.70 | 1.00 | 1.43 | 1.17 | 1.79 | 1.88 | 1.75 | 2.48 | |||||||||||
| Operating & Other expenses | 2.63 | 1.40 | 2.34 | -0.23 | 1.92 | -3.50 | 11.69 | -1.33 | 1.80 | |||||||||||
EBITDA | -4.16 | -4.23 | -2.64 | -1.73 | -3.84 | 6.13 | 2.02 | -7.83 | -9.62 | -8.42 | ||||||||||
| Depreciation/Amortization | 0.82 | 0.90 | 0.94 | 1.02 | 1.00 | 1.20 | 1.59 | 2.05 | 2.66 | 2.66 | ||||||||||
| PBIT | -4.98 | -5.13 | -3.58 | -2.75 | -4.84 | 4.93 | 0.43 | -9.88 | -12.28 | -11.08 | ||||||||||
| Interest & Other Items | 0.51 | 0.60 | 0.90 | 0.75 | 1.09 | 1.78 | 0.92 | 1.49 | 1.59 | 2.08 | ||||||||||
| PBT | -5.49 | -5.73 | -4.48 | -3.50 | -5.93 | 3.15 | -0.49 | -11.37 | -13.87 | -13.16 | ||||||||||
| Taxes & Other Items | 0.00 | 0.09 | 0.05 | -0.24 | -0.15 | 0.21 | 0.12 | 0.20 | -10.39 | -13.00 | ||||||||||
| Net Income | -5.49 | -5.82 | -4.53 | -3.26 | -5.78 | 2.94 | -0.61 | -11.57 | -3.48 | -0.16 | ||||||||||
| EPS | -5.38 | -5.71 | -4.44 | -3.20 | -5.67 | 2.88 | -0.50 | -8.15 | -1.46 | -0.05 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
OXYGENTAPH Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFOXYGENTAPH Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Oxygenta Pharmaceutical Ltd | -95.09 | -16.44 | — |
| Sun Pharmaceutical Industries Ltd | 43.35 | 6.19 | 0.78% |
| Cipla Ltd | 22.85 | 4.49 | 1.07% |
| Torrent Pharmaceuticals Ltd | 67.49 | 16.30 | 0.85% |
OXYGENTAPH Stock Price Comparison
Compare OXYGENTAPH with any stock or ETFCompare OXYGENTAPH with any stock or ETF
OXYGENTAPH
OXYGENTAPH Shareholdings
OXYGENTAPH Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 2.16%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
OXYGENTAPH Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
OXYGENTAPH Shareholding Pattern
OXYGENTAPH Shareholding History
Foreign Institutions
smallcases containing OXYGENTAPH stock
Looks like this stock is not in any smallcase yet.
OXYGENTAPH Events
OXYGENTAPH Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
OXYGENTAPH has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
OXYGENTAPH Dividends
Hmm, looks like data is unavailable here. Please come back after some timeOXYGENTAPH Stock News & Opinions
Articles & Videos
Earnings
Oxygenta Pharmaceutical reports standalone net loss of Rs 3.93 crore in the December 2024 quarter
Net Loss of Oxygenta Pharmaceutical reported to Rs 3.93 crore in the quarter ended December 2024 as against net loss of Rs 3.78 crore during the previous quarter ended December 2023. Sales rose 262.95% to Rs 33.21 crore in the quarter ended December 2024 as against Rs 9.15 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales33.219.15 263 OPM %-13.10-27.10 - PBDT-4.25-2.81 -51 PBT-4.96-3.50 -42 NP-3.93-3.78 -4 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Oxygenta Pharmaceutical to convene board meeting
Oxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Oxygenta Pharmaceutical announces board meeting date
Oxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Oxygenta Pharmaceutical reports standalone net loss of Rs 2.85 crore in the September 2024 quarter
Net Loss of Oxygenta Pharmaceutical reported to Rs 2.85 crore in the quarter ended September 2024 as against net loss of Rs 3.16 crore during the previous quarter ended September 2023. Sales rose 7.11% to Rs 14.01 crore in the quarter ended September 2024 as against Rs 13.08 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales14.0113.08 7 OPM %-15.49-15.14 - PBDT-2.11-2.32 9 PBT-2.77-3.15 12 NP-2.85-3.16 10 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Oxygenta Pharmaceutical announces board meeting date
Oxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Oxygenta Pharmaceutical schedules AGM
Oxygenta Pharmaceutical announced that the 31th Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Earnings
Oxygenta Pharmaceutical reports standalone net loss of Rs 1.36 crore in the June 2024 quarter
Net Loss of Oxygenta Pharmaceutical reported to Rs 1.36 crore in the quarter ended June 2024 as against net loss of Rs 4.56 crore during the previous quarter ended June 2023. Sales rose 83.97% to Rs 12.62 crore in the quarter ended June 2024 as against Rs 6.86 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales12.626.86 84 OPM %-14.03-53.06 - PBDT-2.16-3.93 45 PBT-2.81-4.43 37 NP-1.36-4.56 70 Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Oxygenta Pharmaceutical to discuss results
Oxygenta Pharmaceutical will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 13.8%, vs industry avg of 9.04%
Over the last 5 years, market share stayed at 0.01%